CLINICAL TRIALS PROFILE FOR BREYANZI
✉ Email this page to a colleague
All Clinical Trials for BREYANZI
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT05359211 ↗ | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Not yet recruiting | Nektar Therapeutics | Phase 1 | 2022-05-01 | This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Lisocabtagene maraleucel is a CAR-T cell product that consists of genetically engineered T cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 together with lisocabtagene maraleucel may work better in treating large B-cell lymphoma than either drug alone. |
| NCT05359211 ↗ | NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma | Not yet recruiting | Fred Hutchinson Cancer Center | Phase 1 | 2022-05-01 | This phase Ib trial studies the effects of NKTR-255 in combination with chimeric antigen (CAR)-T cell therapy and to see how well they work in treating patients with large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Lisocabtagene maraleucel is a CAR-T cell product that consists of genetically engineered T cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 together with lisocabtagene maraleucel may work better in treating large B-cell lymphoma than either drug alone. |
| NCT05583149 ↗ | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | Not yet recruiting | AstraZeneca | Phase 2 | 2022-10-01 | This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce |
| NCT05583149 ↗ | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas | Not yet recruiting | Jeremy Abramson, MD | Phase 2 | 2022-10-01 | This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma. This research study involves the study drug acalabrutinib in combination with lisocabtagene maraleuce |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BREYANZI
Condition Name
| Condition Name for BREYANZI | |
| Intervention | Trials |
| Refractory Diffuse Large B-Cell Lymphoma | 2 |
| Recurrent Diffuse Large B-Cell Lymphoma | 2 |
| Refractory Transformed Chronic Lymphocytic Leukemia | 2 |
| Recurrent Transformed Chronic Lymphocytic Leukemia | 2 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for BREYANZI
Trials by Country
Clinical Trial Progress for BREYANZI
Clinical Trial Phase
Clinical Trial Sponsors for BREYANZI
Sponsor Name
